Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2020 August;155(4) > Giornale Italiano di Dermatologia e Venereologia 2020 August;155(4):400-10

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  CURRENT AND FUTURE ORAL THERAPIES FOR PSORIASIS AND PSORIATIC ARTHRITIS Freefree

Giornale Italiano di Dermatologia e Venereologia 2020 August;155(4):400-10

DOI: 10.23736/S0392-0488.20.06643-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Arvin IGHANI 1, Jorge R. GEORGAKOPOULOS 1, Jensen YEUNG 1, 2, 3, 4

1 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada; 2 Division of Dermatology, Department of Medicine, Women’s College Hospital, Toronto, ON, Canada; 3 Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 4 Probity Medical Research Inc., Waterloo, ON, Canada



INTRODUCTION: Tofacitinib is a novel oral janus kinase (JAK) inhibitor approved for the treatment of psoriatic arthritis. It was also investigated for the treatment of plaque psoriasis, although it is not approved by the Food and Drug Administration for this indication. This article aimed to summarize the efficacy and safety data of tofacitinib for treatment of psoriatic disease.
EVIDENCE ACQUISITION: A comprehensive review of literature was conducted on the PubMed database using the search terms: “((tofacitinib) AND (psoriasis)) OR ((tofacitinib) AND (psoriatic arthritis))”. Data from the pivotal clinical trials evaluating tofacitinib in the treatment of psoriatic disease were summarized.
EVIDENCE SYNTHESIS: The Oral-treatment Psoriasis Trial (OPT) study series demonstrated that tofacitinib is efficacious in the treatment of plaque psoriasis with an acceptable safety profile. The OPT studies also demonstrated the non-inferiority of tofacitinib 10 mg twice daily compared to etanercept. The Oral Psoriatic Arthritis Trial (OPAL) study series demonstrated that tofacitinib significantly improved psoriatic arthritis outcomes compared to placebo and had an acceptable safety profile. Its efficacy is comparable to adalimumab in psoriatic arthritis.
CONCLUSIONS: Patients treated with tofacitinib should be monitored for herpes zoster, malignancies, blood clots, and changes in laboratory values. Overall, tofacitinib is a useful new systemic agent in the treatment of psoriatic disease. Its oral route of administration, novel JAK pathway target, short half-life, and strong recapture rates after treatment interruption make it a unique new tool for psoriatic disease management. Further long-term studies will help determine its role in the treatment algorithm for psoriatic arthritis and its indication for plaque psoriasis.


KEY WORDS: Tofacitinib; Janus kinase inhibitor; Psoriasis; Arthritis, psoriatic; Safety

inizio pagina